Additionally, it preliminarily explored the mechanism by which MAT exerts its therapeutic effect on RA, which involves the inhibition of the NAV2-Wnt3a-β-catenin signaling pathway. This evidence concerns the gene WNT3A and rheumatoid arthritis.